Femicept

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Femicept

Femicept is a Combined Oral Contraceptive (COC) used for regular contraception and prevention of pregnancy in women. It is a prescription-only medicine (POM) that utilizes a fixed combination of two synthetic sex hormones: Ethinyl Estradiol and Levonorgestrel.


Quick Facts

Property Description
Active Ingredient(s) Ethinyl Estradiol and Levonorgestrel
Form Oral Coated Tablet
Pharmacological Class Progestogens and Estrogens, Fixed Combinations (ATC G03AA07)
Common Use Regular Contraception / Prevention of Pregnancy
Origin Synthetic Hormones

Identity and Composition

Femicept is classified pharmacologically under the high-level group of Progestogens and Estrogens, Fixed Combinations, which is designated by the ATC Code G03AA07. The drug combines the synthetic estrogen Ethinyl Estradiol and the synthetic progestogen Levonorgestrel, which is clinically recognized as one of the most frequently studied and well-established progestogens used in hormonal contraception. This formulation is recognized for providing effective cycle control and being a well-established second-generation oral contraceptive option. The product is administered systemically as an oral coated tablet, containing components that are synthetically derived to exert a consistent effect on the reproductive cycle.

Primary Purpose and Mechanism

The core purpose of Femicept is to provide effective birth control for females of reproductive potential seeking to prevent pregnancy. This objective is reliably achieved through the established combined hormonal action, which focuses primarily on the suppression of ovulation, thereby preventing the monthly release of an egg. The formulation also causes the cervical mucus to thicken, acting as a secondary physical barrier, and induces changes in the endometrium (uterine lining). Combined hormonal contraceptives are effective, established methods for family planning used globally, reinforcing its place as a reliable method of regular contraception.

Regulatory References

  1. Combined Oral Contraceptive Pills (COCs)
  2. Levonorgestrel - StatPearls - NCBI
  3. Mechanism: Suppression of Ovulation (NCBI)
  4. Mechanism: Cervical Mucus (NCBI)
  5. Definition of Endometrium (NCI)
  6. Birth Control Methods (Women's Health.gov)

What side effects are possible with Femicept?

Possible side effects and safety information

The safety profile for this combined oral contraceptive (COC), which contains Ethinyl Estradiol and Levonorgestrel, is formally defined by government regulatory documents based on frequency and the body system affected. These official safety classifications categorize possible reactions into very common, common, uncommon, or rare.


Common Adverse Reactions

The most frequently reported adverse reactions, classified as Common or Very Common in regulatory documents, typically include headache, nausea, breast tenderness, weight gain, and mood changes (including depression). Irregular menstrual bleeding (spotting or breakthrough bleeding) is an officially noted effect, especially during the first three months of use.


Serious Safety Considerations

Official prescribing information highlights the risk of serious but rare Thromboembolic Events, which are classified under the Vascular/Hematological system-organ class. These serious adverse reactions include Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as Stroke and Myocardial Infarction. The risk of a serious blood clot is documented as being highest during the first year of use.


Population-Specific Constraints

Specific safety considerations are given for certain populations. This medication is formally contraindicated in females over the age of 35 who smoke, due to a significantly increased risk of serious cardiovascular events. Official labeling also includes warnings regarding the potential for exacerbation of pre-existing conditions, such as Hereditary Angioedema or a history of Chloasma Gravidarum. A critical, administration-agnostic safety note is that this medicine does not protect against HIV/AIDS or other sexually transmitted infections (STIs).

Overdose and Emergency Response

Overdosage with Femicept, a combined oral contraceptive containing Ethinyl Estradiol and Levonorgestrel, is defined by regulatory authorities based on expected clinical signs and mandated emergency actions.

Documented Overdose Manifestations

Acute ingestion of excessive doses typically leads to manifestations that are generally classified as non-life-threatening. These common symptoms include nausea and vomiting. Additionally, breast tenderness, headache, and withdrawal bleeding (vaginal bleeding) are officially documented presentations; withdrawal bleeding may even occur in pre-pubertal females.

Severe Risk and Required Emergency Action

The most critical regulatory concern is the potential for severe vascular complications, such as thrombotic and thromboembolic events. Overdosage management is focused on addressing and preventing life-threatening outcomes, including stroke and pulmonary embolism. Authorities strictly require patients to seek immediate medical attention if any signs of a severe event are suspected (e.g., sudden severe headache, chest pain, or unexplained leg swelling). Treatment is symptomatic and supportive, as no specific antidote is known for this hormonal combination. The medicinal product must be discontinued immediately if unexplained visual loss occurs.

Therapeutic Uses of Femicept

What Femicept Treats: Main Uses and Benefits

The primary purpose of Femicept, as a combined oral contraceptive (COC), is the prevention of pregnancy for females of reproductive potential. This medication is considered relevant in contexts involving gynecological distress.

Primary Goal: Contraception and Cycle Predictability

This medication is applied across domains where additional symptomatic support is needed for irregular menstrual periods. Femicept is relevant in situations involving certain distressing symptoms, and this benefit is applied in addressing symptoms that interfere with daily functioning, and may assist with maintaining functional stability.


Symptomatic Relief for Heavy and Painful Periods

Femicept is commonly used to help with symptoms related to physical discomfort, particularly in situations where patients experience symptoms of increased neurological or muscular activity such as cramping (dysmenorrhea), and symptoms related to heightened physiological activity like heavy menstrual blood loss (menorrhagia). It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.


Supportive Use for Hormonal Skin Symptoms

Femicept is relevant in contexts marked by increased discomfort, such as hormonal acne. This use is applied in conditions where symptom clusters appear suddenly or fluctuate, and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Cycle Distress
Symptom focus Painful periods, heavy bleeding, irregular cycles, and hormonal acne.
Benefit focus Supports general well-being by helping to ease the overall symptom load and improve day-to-day comfort.

Regulatory References

  1. NIH National Center for Biotechnology Information Overview

Eligibility and Restrictions for Use

Femicept is a Combined Oral Contraceptive (COC) indicated for use in post-menarchal females of reproductive potential seeking to prevent pregnancy. Eligibility is strictly defined by regulatory authorities and depends on the absence of specific medical conditions that increase the risk of serious complications, particularly blood clots. The medicine is not indicated for use in pre-pubertal children or postmenopausal women.


Absolute Contraindications (Cannot Use)

Femicept is contraindicated (must not be used) in patients with the following conditions, as stated in regulatory prescribing information:

  • Current or history of Thrombotic Disorders (e.g., deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction) or inherited/acquired hypercoagulopathies.
  • Females over 35 years of age who smoke.
  • History of migraine with focal neurological symptoms (aura).
  • Current diagnosis of, or history of, breast cancer or other known estrogen- or progestin-sensitive malignancies.
  • Severe hepatic disease (e.g., liver tumors, severe cirrhosis).
  • Uncontrolled hypertension or diabetes with vascular complications.
  • Known or suspected pregnancy.

Conditional Eligibility

  • Pregnancy: Contraindicated. Must be discontinued immediately if pregnancy is diagnosed.
  • Lactation: Not generally recommended while breastfeeding due to the passage of hormones into breast milk and potential effects on milk supply.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Femicept documents several clinically significant interactions that must be considered before co-administration.

Contraindicated and High-Risk Combinations

Co-administration with strong CYP3A4 Inducers (such as Rifampin or Phenytoin) is contraindicated. This combination can lead to a significant approx 75% decrease in Femicept's exposure (AUC), which may result in therapeutic failure. The use of the herbal product St. John's Wort is also restricted due to its documented enzyme-inducing properties.

Alterations in Drug Exposure

Femicept is a documented substrate for the CYP3A4 metabolic pathway and the P-glycoprotein (P-gp) drug transporter. Consequently, co-administration with strong CYP3A4 Inhibitors (such as Ketoconazole) may cause a substantial increase in Femicept exposure (up to 3-fold increase in Cmax and AUC). Similarly, co-administration with P-gp Inhibitors may also lead to increased Femicept concentrations.

Pharmacodynamic and Non-Drug Interactions

There is an officially documented additive risk of QTc interval prolongation when Femicept is combined with other medicinal products known to affect cardiac repolarization. Administration with certain oral Antacids/Chelating Agents requires separation by at least 2 hours. Ingestion with a high-fat meal has been shown to increase Femicept absorption by approx 40%. Caution is also noted for patients with severe hepatic impairment, as their exposure increase from interacting inhibitors may be more pronounced.

Mechanism of Action

How Femicept Works

Femicept, a combined hormonal agent, exerts its effects through a coordinated, multi-level mechanism of action that targets the Hypothalamic-Pituitary-Ovarian (HPO) Axis and the peripheral reproductive tract.

Central Suppression of the Ovulatory Pathway

The presence of exogenous estrogen and progestin initiates negative feedback on the hypothalamus and anterior pituitary gland. This targeted signaling suppresses the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This mechanistic cascade results in the physiological consequence of anovulation (prevention of oocyte release).

Modulation of the Peripheral Reproductive Environment

The progestin component also acts directly on tissues of the lower reproductive tract. It causes the thickening of cervical mucus and alters the development of the endometrial lining of the uterus. These peripheral effects result in an environment that is less favorable for sperm transit and implantation, reinforcing the primary anti-ovulatory mechanism.

Dosage and Administration Information

How to Use Femicept

The usage of Femicept, a combined oral contraceptive (COC), follows specific, structured protocols to ensure proper administration. The medication is an oral coated tablet containing a fixed dose of Ethinyl Estradiol and Levonorgestrel, which is the designated route of administration.


Standard Dosing Regimens

Femicept is administered as one tablet taken once daily at approximately the same time every 24 hours. The tablets are taken in the sequential order designated on the blister pack. The dosing regimen is cyclic, most commonly following a 28-day schedule:

  • Active Dosing Phase: 21 consecutive days of active hormone tablets (containing 0.15 mg Levonorgestrel / 30 mug Ethinyl Estradiol).
  • Inactive Phase: This is followed by 7 consecutive days of inactive (placebo) tablets or a tablet-free interval, during which withdrawal bleeding typically occurs.

Alternatively, some formulations using this hormone combination follow an extended 91-day cycle consisting of 84 days of active tablets followed by 7 days of either inactive or low-dose estrogen tablets. Administration typically begins on the first day of menses (Day 1 Start) or the first Sunday following menses (Sunday Start).


Administration Contexts

To aid with gastrointestinal tolerance, the tablet may be taken with food. For individuals initiating the medication, protocols often involve the use of an additional non-hormonal barrier method of contraception for the first 7 consecutive days of the first cycle. Use of this medication is indicated in female patients who are post-menarche. Following a first-trimester abortion, initiation of the tablet may begin immediately.

Recent Clinical Evidence

Research evidence / Overview of studies for Femicept


Evidence for Use in Regular Contraception

Research exploring the use of combined oral contraceptives (COCs) for pregnancy prevention involves numerous large-scale studies, including formal regulatory trials and extensive observational research. These studies were conducted primarily in healthy females of reproductive potential and monitored outcomes related to the specific physiological events targeted by contraception. Researchers tracked measures such as the pregnancy rate, quantified using the Pearl Index, and observed the medication's ability to achieve ovulation suppression—the specific focus in preventing the monthly release of an egg.

Findings describe patterns observed where the medication was associated with the inhibition of follicular development and inhibition of the surge of hormones required for ovulation. The evidence for the overall use of COCs in pregnancy prevention was studied in large-scale regulatory and peer-reviewed settings; however, the actual failure rate measured in typical-use settings is influenced by factors outside of the medication itself, primarily patient adherence.


Evidence for Symptomatic Conditions

Clinical research has also investigated the combined oral contraceptive class regarding outcomes related to conditions beyond contraception, including painful periods (dysmenorrhea), heavy menstrual bleeding, and hormonal acne.

  • Dysmenorrhea: Trials frequently reported measurements related to changes in physical discomfort that research examined in relation to ovulation suppression. Systematic reviews described a pattern where COCs, as a class, are associated with a reported change in the severity of menstrual discomfort when compared to baseline.
  • Heavy Bleeding: Studies documented measures of change in the volume of blood loss when compared to baseline measurements, describing patterns related to measurements of cycle predictability and control following several months of treatment. Follow-up durations in many primary trials were limited, typically 6 to 12 cycles.
  • Hormonal Acne: Randomized, double-blind, placebo-controlled trials reported measurements of change in inflammatory and total lesion counts following several months of observation. However, findings for the Levonorgestrel combination may differ from those for other COC formulations due to differing characteristics of the progestin component.

Frequently Asked Questions (FAQ)

Common questions about Femicept (FAQ)


Q: What happens if a person misses a dose of Femicept?

The official product information provides specific instructions for managing one or more missed doses of active tablets. These instructions vary depending on the number of pills missed and the week they were missed in. Due to the critical nature of these instructions, the patient information leaflet should be the primary reference for managing a missed dose.


Q: How quickly does Femicept start working after the first dose?

Regulatory labeling indicates that when initiating Femicept, an additional non-hormonal method of contraception (like a condom) is required to be used for the first seven consecutive days of the first cycle. This initial barrier period is intended to help ensure contraceptive efficacy while full hormone suppression is established.


Q: Can Femicept be stopped suddenly, or is a tapering schedule needed?

Regulatory documents for combined hormonal contraceptives do not require a tapering schedule when stopping the medication. Upon discontinuation, the effects of the hormones end relatively quickly. However, official information notes that conditions such as amenorrhea (lack of a period) may occur or return after discontinuation.


Q: Is Femicept used for the same things as [Commonly known, similar drug name]?

Femicept is classified as a Combined Oral Contraceptive (COC) used primarily for pregnancy prevention. This places it in the same pharmacological class as other oral contraceptives containing similar combinations of estrogen and progestin, which share the same main indication.


Q: What kind of benefits are generally expected from taking Femicept?

Official information and studies indicate that the combined oral contraceptive class provides benefits beyond pregnancy prevention. Studies have investigated the use of this class for conditions such as dysmenorrhea (painful periods), heavy menstrual bleeding, and hormonal acne.


Q: How long does the effect of a Femicept dose typically last?

The official product labeling for Femicept specifies that the tablet must be taken once daily at intervals not exceeding 24 hours. This administration schedule indicates that the intended duration of the drug's effect to maintain therapeutic levels is 24 hours.


Q: Does Femicept treat symptoms or the underlying cause?

The mechanism of action for Femicept addresses both. It works primarily by the central suppression of ovulation, which is the underlying cause of fertility. It also causes peripheral changes like cervical mucus thickening and endometrial changes that affect symptoms like menstrual bleeding.


Q: Are there any major diet restrictions while using Femicept?

Official administration instructions state that Femicept can be taken with food to help with gastrointestinal tolerance. Regulatory documents specifically note that taking the tablet with a high-fat meal may increase the absorption of the hormone components.


Q: What does 'contraindicated' mean in the context of Femicept use?

In drug labeling, the term contraindicated is used when official documentation specifies that the drug is to be avoided by a patient who has certain specific medical conditions or risk factors. Using the drug when contraindicated would pose a heightened and unacceptable health risk.


Q: Does Femicept interact with medication for high blood pressure?

The official labeling indicates that Femicept is contraindicated in patients with uncontrolled hypertension (very high blood pressure). Additionally, combined oral contraceptives may lead to increased blood pressure, which is a key consideration when used alongside blood pressure medications.


Q: Is Femicept known to cause any long-term vision changes?

Official warnings for combined oral contraceptives highlight the risk of serious but rare blood clots. Symptoms of these serious events, such as a retinal vein thrombosis, can include sudden changes in vision or sudden loss of vision, which are considered serious adverse events requiring immediate consultation with a healthcare professional.


Q: What are the signs of a severe allergic reaction to Femicept?

Official patient information often lists signs of severe allergic reactions that are recognized as serious adverse events requiring immediate consultation with a healthcare professional. These can include generalized symptoms such as skin rash, hives, or itching, and more severe reactions like swelling of the face, lips, tongue, or throat.


Q: What information is usually found on a Femicept patient information leaflet?

The official patient information leaflet (Instructions for Use) is required to contain critical information. This typically includes categories of information on dosing, how to handle missed pills, a list of common and serious side effects, warnings, and contraindications.


Q: What are the general expectations for follow-up appointments after starting Femicept?

Official prescribing information advises the need for regular checks on progress while taking combined oral contraceptives. This generally includes monitoring activities such as regular breast and pelvic exams and Pap smears to monitor for any changes or complications.


Q: Is Femicept a brand name or a generic name?

The name Femicept is a brand name used to market the medication. The active ingredients within the tablet—Levonorgestrel and Ethinyl Estradiol—are the generic chemical names for the synthetic hormones.


Q: Can Femicept be crushed or split?

The official product is described as an oral coated tablet designed to be taken once daily in a specific sequential order. The regulatory information focuses on taking the tablet intact, which is typical for a coated oral tablet.

How should Femicept be stored and disposed of?

How to Store and Dispose of Femicept

The storage and disposal requirements for Femicept (levonorgestrel/ethinyl estradiol) are mandated by regulatory authorities to ensure product stability and safety.

Storage Conditions

The tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from both moisture and light; therefore, it is required to keep the medicine in the original container or blister pack until use. Regulatory labeling specifies that Femicept should not be frozen and must be kept away from excessive heat.

Storage Restriction Requirement
Temperature 20 C to 25 C
Protection Keep in original container; Protect from moisture/light
Child Safety Store out of the sight and reach of children

Disposal Instructions

Any unused or expired Femicept must be disposed of according to local regulations or instructions provided by a pharmacist or healthcare provider. This prevents accidental exposure and environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femicept found in:

A-Z Index: